Literature DB >> 12584041

Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation.

A Fahrleitner1, G Prenner, G Leb, K H Tscheliessnigg, C Piswanger-Sölkner, B Obermayer-Pietsch, H R Portugaller, A Berghold, H Dobnig.   

Abstract

Osteoprotegerin (OPG) is an antiresorptive cytokine and a key regulator of osteoclastogenesis and activity. Since OPG is downregulated by glucocorticoids and cyclosporine A in vitro we examined whether immunosuppressive therapy would play a role in the development of transplantation osteoporosis. We enrolled 57 cardiac transplant recipients (median time since transplantation, 3.2 years (1.1-11.5 years)) in this cross-sectional study. Standardized spinal X-rays as well as hip bone density measurements were performed in all patients. Serum OPG was determined using a commercially available ELISA. Vertebral fractures were present in 56% of the patients. Bone densities of all femoral neck subregions were correlated to serum OPG concentrations (r values between 0.40 and 0.48, all P < 0.005). Multiple regression analysis revealed OPG levels to be independently correlated to femoral neck Z scores (r = 0.49, P = 0.002). After adjustment for age, BMI, neck Z score, renal function, and months since transplantation, serum OPG was the only significant predictor of prevalent vertebral fractures (P = 0.001). In a separate 6-month prospective study of 14 heart transplant recipients receiving calcium and vitamin D serum OPG levels fell by 41% (P = 0.0004) after 3 months and 47% (P = 0.0001) after 6 months following cardiac transplantation. Bone loss at the lumbar spine and femoral neck after 6 months was correlated to the decrease in serum OPG at 6 months (r = 0.82, P < 0.0001, and r = 0.60, P = 0.02, respectively) as well as 3 months after cardiac transplantation (r = 0.65, P = 0.01, and r = 0.69, P = 0.006, respectively). Serum OPG alone accounted for 67% of the variance of lumbar spine bone density changes over the first 6 months posttransplantation. We conclude that serum OPG levels decline consistently in all patients following initiation of immunosuppressive therapy and are independently correlated with changes in bone density. We hypothesize that OPG plays a major role in the development of transplantation osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12584041     DOI: 10.1016/s8756-3282(02)00926-2

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  13 in total

1.  Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss?

Authors:  K Kananen; L Volin; K Laitinen; T Ruutu; M J Välimäki
Journal:  Osteoporos Int       Date:  2005-12-31       Impact factor: 4.507

2.  Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover.

Authors:  Olafur S Indridason; Leifur Franzson; Gunnar Sigurdsson
Journal:  Osteoporos Int       Date:  2004-07-20       Impact factor: 4.507

3.  Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status.

Authors:  Astrid Fahrleitner-Pammer; Harald Dobnig; Claudia Piswanger-Soelkner; Christine Bonelli; Hans-Peter Dimai; Georg Leb; Barbara Obermayer-Pietsch
Journal:  Wien Klin Wochenschr       Date:  2003-05-15       Impact factor: 1.704

Review 4.  Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: are they of any help?

Authors:  Doris Wagner; Astrid Fahrleitner-Pammer
Journal:  Wien Med Wochenschr       Date:  2010-08-16

5.  Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children.

Authors:  Anna Wasilewska; Agnieszka Rybi-Szuminska; Walentyna Zoch-Zwierz
Journal:  Pediatr Nephrol       Date:  2010-07-04       Impact factor: 3.714

6.  The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club.

Authors:  E Cavalier; P Bergmann; O Bruyère; P Delanaye; A Durnez; J-P Devogelaer; S L Ferrari; E Gielen; S Goemaere; J-M Kaufman; A Nzeusseu Toukap; J-Y Reginster; A-F Rousseau; S Rozenberg; A J Scheen; J-J Body
Journal:  Osteoporos Int       Date:  2016-03-30       Impact factor: 4.507

7.  Osteoprotegerin Lys3Asn polymorphism and the risk of fracture in older women.

Authors:  S P Moffett; J I Oakley; J A Cauley; L Y Lui; K E Ensrud; B C Taylor; T A Hillier; M C Hochberg; J Li; S Cayabyab; J M Lee; G Peltz; S R Cummings; J M Zmuda
Journal:  J Clin Endocrinol Metab       Date:  2008-03-04       Impact factor: 5.958

Review 8.  Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

Authors:  Ann E Kearns; Sundeep Khosla; Paul J Kostenuik
Journal:  Endocr Rev       Date:  2007-12-05       Impact factor: 19.871

9.  Show a heart for bones in time--fractures remain a common problem following cardiac transplantation.

Authors:  Harald Dobnig
Journal:  Wien Klin Wochenschr       Date:  2004-03-31       Impact factor: 2.275

Review 10.  Mechanism and Treatment Strategy of Osteoporosis after Transplantation.

Authors:  Lei Song; Xu-Biao Xie; Long-Kai Peng; Shao-Jie Yu; Ya-Ting Peng
Journal:  Int J Endocrinol       Date:  2015-07-27       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.